摘要:
An assembly and method for processing extrudate material containing curves or angles into a predetermined overall configuration, including having a die assembly for an extruder which assembly controls the cross-sectional shape or profile of the extrudate and selectively varies the path of the extrudate as it leaves the die assembly. A support member is provided which has a predetermined overall configuration and profile to receive the extrudate and maintain its configuration. A driving apparatus is also provided for continuously driving either the support member or the die assembly relative to the other while the extrudate is being received in the support member, and until the entire predetermined overall configuration has been completed. The path of the extrudate is variably directed by the die assembly as it leaves the extruder in coordination with the relative speeds involved to conform the extrudate configuration to the predetermined overall configuration of the support member.
摘要:
A die assembly for configuring extrudate flow is provided. The die assembly includes a die head having a feed member passage, first and second die head passages, and first and second die surfaces respectively associated with the first and second die head passages. The die head passages are located intermediate the corresponding die surfaces and the feed member passage. A feed member is supported in the feed member passage of the die head and has a feed passage and a feed opening for supplying extrudate to the die head. The feed member is supported for relative movement within the die head whereby the feed opening may be moved to communicate with either the first die head passage or the second die head passage. The central axis feed of the feed opening is moveable with respect to the central axis of the first or second die head passage to correspondingly configure extrudate exiting the respective die head passage when the feed opening is in communication with this die head passage. The die assembly may also include a switch member whereby the die assembly may be supplied with extrudate material from either a first or second extruder.
摘要:
The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
摘要:
Compounds of formula (I) and (II) are disclosed wherein, R1, R2, R3, R4, X, A, B, D and Q are as disclosed in the specification, and the compounds are FabI inhibitors useful in the treatment of bacterial infections.
摘要:
A compound of the formula (I) is disclosed which is a vitronectin receptor antagonist and is useful in the treatment of osteoporosis: or a pharmaceutically acceptable salt thereof.
摘要:
Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form --(CHR.sup.g).sub.a --U--(CHR.sup.g).sub.b --V--; Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 are independently N or C--R.sup.y, provided that no more than one Q.sup.1, Q.sup.2, Q.sup.3 and Q.sup.4 is N; R' is H or C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 -alkyl or Ar--C.sub.0-6 alkyl; R.sup.g is H or C.sub.1-6 alkyl, Het-C.sub.0-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl or Ar--C.sub.0-6 alkyl; R.sup.k is R.sup.g, --C(O)R.sup.g or --C(O)OR.sup.g R.sup.i is H, C.sub.1-6 alkyl, Het-C.sub.0-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl, Ar--C.sub.0-6 alkyl, Het-C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl-C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl or Ar--C.sub.0-6 alkyl--U'--C.sub.1-6 alkyl; R.sup.y is H, halo, --OR.sup.g, --SR.sup.g, --CN, --NR.sup.g R.sup.k, --NO.sub.2, --CF.sub.3, CF.sub.3 S(O).sub.r, --CO.sub.2 R.sup.g, --COR.sup.g or --CONR.sup.g.sub.2, or C.sub.1-6 alkyl optionally substituted by halo, --OR.sup.g, --SR.sup.g, --CN, --NR.sup.8 R", --NO.sub.2, --CF.sub.3, R'S(O).sub.3 --, --CO.sub.2 R.sup.g, --COR.sup.g or --CONR.sup.g.sub.2 ; U and V are absent or CO, CR.sup.g.sub.2, C(.dbd.CR.sup.g.sub.2), S(O).sub.c, O, NR.sup.g, CR.sup.g OR.sup.g, CR.sup.g (OR.sup.k)CR.sup.g.sub.2, CR.sup.g.sub.7 CR.sup.g (OR.sup.k), C(O)CR.sup.g.sub.2, CR.sup.g.sub.2 C(O), CONR.sup.i, NR.sup.i CO, OC(O), C(O)O, OC(S), C(S)NR.sup.g, NR.sup.8 C(S), S(O.sub..sub.2 NR.sup.g, NR.sup.g S(O).sub.2 N.dbd.N, NR.sup.g NR.sup.g, NR.sup.g CR.sup.g.sub.2, NR.sup.g CR.sup.g.sub.2, CR.sup.g.sub.2 O, OCR.sup.g.sub.2, CR.sup.g .dbd.CR.sup.g, C.ident.C, Ar or Het; a is 0, 1 or 2; c is 0, 1 or 2; r is 0, 1 or 2; and u is 0 or 1; or pharmaceutically acceptable salts thereof, which are vitronectin receptor antagonists useful in the treatment of osteoporosis. ##STR1##
摘要翻译:PCT No.PCT / US96 / 20327 Sec。 371日期:1999年7月27日 102(e)日期1999年7月27日PCT 1996年12月20日PCT PCT。 公开号WO97 / 24124 日期1999年7月10日公开了式(I)的化合物,其中:A是纤维蛋白原拮抗剂模板; W是 - (CHRg)a-U-(CHRg)b-V-的形式的连接部分; Q1,Q2,Q3和Q4独立为N或C-Ry,条件是不超过一个Q1,Q2,Q3和Q4为N; R'是H或C 1-6烷基,C 3-7环烷基-C 0-6 - 烷基或Ar-C 0-6烷基; R g是H或C 1-6烷基,Het-C 0-6烷基,C 3-7环烷基-C 0-6烷基或Ar-C 0-6烷基; R k是R g,-C(O)R g或-C(O)OR g R 1是H,C 1-6烷基,Het-C 0-6烷基,C 3-7环烷基-C 0-6烷基,Ar-C 0-6烷基,Het-C 0-6烷基 -N''-C 1-6烷基,C 3-7环烷基-C 0-6烷基-U'-C 1-6烷基或Ar-C 0-6烷基-U'-C 1-6烷基; R y是H,卤素,-OR g,-SR g,-CN,-NR g R k,-NO 2,-CF 3,CF 3 S(O)r,-CO 2 R g,-COR g或-CONRg 2,或任选被卤素取代的C 1-6烷基,-OR g ,-SRg,-CN,-NR 8 R“,-NO 2,-CF 3,R'(O)3 - ,-CO 2 R g,-COR g或-CONRg 2; U和V不存在或CO,CRg2,C(= CRg2),S(O)c,O,NRg,CRgORg,CRg(ORk)CRg2,CRg7CRg(ORk),C(O)CRg2,CRg2C(O) C(O)O,OC(S),C(S)NR g,NR 8 C(S),S(O 2 NRR,NR g S(O)2 N = N,NR g NRR,NR g CR 2,NR g CR 2, ,OCRg2,CRg = CRg,C = C,Ar或Het; a为0,1或2; c为0,1或2; r为0,1或2; u为0或1;或药学上可接受的盐 它们是可用于治疗骨质疏松症的玻连蛋白受体拮抗剂。
摘要:
A radiation detection system determines the type of nuclear radiation received in a detector by producing a correlation value representative of the statistical cross correlation between the shape of the detector signal and pulse shape data previously stored in memory and characteristic of respective types of radiation. The correlation value is indicative of the type of radiation. The energy of the radiation is determined from the detector signal and is used to produce a spectrum of radiation energies according to radiation type for indicating the nature of the material producing the radiation.
摘要:
A machine for automatically applying a balance correcting weight (44)-and-clip (46) assembly to vehicle wheel-and-tire assembly (12). The machine includes a conveyor (20) portion for conveying the wheel-and-tire assembly (12) to a weight (44) application station, orienting the wheel-and-tire assembly (12) properly to receive at the correct location the balance-correcting weight (44), and conveying the wheel-and-tire assembly (12) to which the balance-correcting weight (44) has been applied away from the weight (44) application station. The machine includes a hammer (22, 24) having a storage orientation out of operating position permitting conveying of the wheel-and-tire assembly (12) to and from the weight (44) application station and a use orientation in operating position adjacent the wheel-and-tire assembly (12) to which balance correcting weight (44) is to be applied, and means for moving the hammer (22, 24) selectively between its storage and use orientations. The hammer (22, 24) includes a jaw (40) with a contour conforming to the shape of the clip (46) and a shank (50) portion of ferromagnetic material, said shank (50) being surrounded by an electrically conductive coil (94).